Zoetis, Inc. discovers, develops and manufactures a portfolio of animal health medicines and vaccines. Its products are complemented by diagnostic products, genetic tests, bio devices and services. These are designed to meet the needs of veterinarians and the livestock farmers and companion animal. The firm provides its services though five categories namely, anti-invectives, vaccines, parasitic ides, medicated feed additives, and other pharmaceuticals. The company was founded in 1952 and is headquartered in New York, NY.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNYSE:ZTS
Previous Symbol
CUSIP98978V10
Phone973-822-7000
Debt
Debt-to-Equity Ratio3.04
Current Ratio4.06
Quick Ratio2.63
Price-To-Earnings
Trailing P/E Ratio37.80
Forward P/E Ratio29.17
P/E Growth1.74
Sales & Book Value
Annual Sales$5.31 billion
Price / Sales8.21
Cash Flow$3.0163 per share
Price / Cash Flow30.08
Book Value$3.67 per share
Price / Book24.72
Profitability
EPS (Most Recent Fiscal Year)$2.40
Net Income$864 million
Net Margins20.35%
Return on Equity75.51%
Return on Assets16.34%
Miscellaneous
Employees9,200
Outstanding Shares480,450,000
Market Cap$42.32 billion
OptionableOptionable
Zoetis (NYSE:ZTS) Frequently Asked Questions
What is Zoetis' stock symbol?
Zoetis trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZTS."
How often does Zoetis pay dividends? What is the dividend yield for Zoetis?
Zoetis declared a quarterly dividend on Wednesday, October 10th. Stockholders of record on Tuesday, November 20th will be paid a dividend of $0.126 per share on Monday, December 3rd. This represents a $0.50 annualized dividend and a dividend yield of 0.56%. The ex-dividend date of this dividend is Monday, November 19th. View Zoetis' Dividend History.
How were Zoetis' earnings last quarter?
Zoetis Inc (NYSE:ZTS) issued its quarterly earnings results on Thursday, November, 1st. The company reported $0.83 earnings per share for the quarter, beating analysts' consensus estimates of $0.77 by $0.06. The company earned $1.48 billion during the quarter, compared to analyst estimates of $1.46 billion. Zoetis had a return on equity of 75.51% and a net margin of 20.35%. The business's revenue was up 9.9% compared to the same quarter last year. During the same period in the previous year, the company posted $0.65 EPS. View Zoetis' Earnings History.
When is Zoetis' next earnings date?
What guidance has Zoetis issued on next quarter's earnings?
Zoetis updated its FY18 earnings guidance on Thursday, November, 1st. The company provided EPS guidance of $3.08-$3.13 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.08. The company issued revenue guidance of $5.75-$5.80 billion, compared to the consensus revenue estimate of $5.78 billion.Zoetis also updated its FY 2018 guidance to $3.08-3.13 EPS.
What price target have analysts set for ZTS?
16 equities research analysts have issued twelve-month price targets for Zoetis' shares. Their forecasts range from $77.00 to $105.00. On average, they anticipate Zoetis' share price to reach $93.60 in the next twelve months. This suggests a possible upside of 3.2% from the stock's current price. View Analyst Price Targets for Zoetis.
What is the consensus analysts' recommendation for Zoetis?
16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zoetis in the last year. There are currently 6 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zoetis.
What are Wall Street analysts saying about Zoetis stock?
Here are some recent quotes from research analysts about Zoetis stock:
- 1. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and raise our 12-month PT for ZTS shares to $105 from $98. The increase in our PT is driven by multiple expansion. Given the company’s durable business model and the positive outlook for macro factors, we think ZTS’s multiple will hold and upwards earnings revisions should drive shares higher. We think ZTS’s multiple will be supported by: 1) its durable business model, 2) positive outlook for macro factors, and 3) solid execution by management. Upwards earnings revisions could come from: 1) higher-than- anticipated peak sales for new launches, 2) better-than-expected operating margins in 2018+, and 3) M&A." (10/17/2018)
- 2. According to Zacks Investment Research, "Zoetis’ companion animal business continues to perform well on higher international sales of Apoquel and Simparica. Growth from new parasiticide products, vaccines and strong dermatology portfolio has also boosted the top-line. The Abaxis acquisition will further strengthen the company’s presence in the animal health diagnostics market, a fast-growing portion of the animal health industry which should further boost sales. Moreover, Zoetis five-year collaboration agreement with Regeneron to research the use of latter’s monoclonal antibody therapeutics in animals and discover new veterinary treatments will further diversify the broad portfolio. Shares of Zoetis have outperformed the industry in the year so far. However, Zoetis faces stiff competition from companies like Merck Animal Health. Disease outbreak among animals is a material cause of concern for livestock products. Estimates are static ahead of Q3 results." (10/17/2018)
Has Zoetis been receiving favorable news coverage?
Press coverage about ZTS stock has been trending very positive on Wednesday, according to InfoTrie. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Zoetis earned a media sentiment score of 3.6 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the next few days.
Who are some of Zoetis' key competitors?
Some companies that are related to Zoetis include AbbVie (ABBV), Abbott Laboratories (ABT), Eli Lilly And Co (LLY), Novo Nordisk A/S (NVO), Sanofi (SNY), AstraZeneca (AZN), GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Shire (SHPG), Allergan (AGN), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN) and ASTELLAS PHARMA/ADR (ALPMY).
Who are Zoetis' key executives?
Zoetis' management team includes the folowing people:
- Juan Ramón Alaix, Chief Executive Officer & Director
- Kristin C. Peck, Executive Vice President & President-US Operations
- Glenn C. David, Chief Financial Officer & Executive Vice President
- Catherine Ann Knupp, Executive VP, President-Research & Development
- Andrew Fenton, Chief Information Officer & Executive VP
Who are Zoetis' major shareholders?
Zoetis' stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.84%), Vanguard Group Inc. (7.48%), Morgan Stanley (3.08%), Alliancebernstein L.P. (2.67%), Polen Capital Management LLC (1.95%) and Clearbridge Investments LLC (1.82%). Company insiders that own Zoetis stock include Catherine A Knupp, Glenn David, Heidi C Chen, Juan Ramon Alaix, Khosla Sanjay, Kristin C Peck, Roman Trawicki, Roxanne Lagano and Willie M Reed. View Institutional Ownership Trends for Zoetis.
Which major investors are selling Zoetis stock?
ZTS stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Mitsubishi UFJ Trust & Banking Corp, Alliancebernstein L.P., TIAA CREF Investment Management LLC, Wells Fargo & Company MN, Atalanta Sosnoff Capital LLC, Brown Brothers Harriman & Co. and Jennison Associates LLC. Company insiders that have sold Zoetis company stock in the last year include Catherine A Knupp, Glenn David, Heidi C Chen, Juan Ramon Alaix, Khosla Sanjay, Kristin C Peck, Roman Trawicki, Roxanne Lagano and Willie M Reed. View Insider Buying and Selling for Zoetis.
Which major investors are buying Zoetis stock?
ZTS stock was acquired by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Renaissance Technologies LLC, Marshall Wace North America L.P., Deutsche Bank AG, AQR Capital Management LLC, Capital World Investors, FMR LLC and BlackRock Inc.. View Insider Buying and Selling for Zoetis.
How do I buy shares of Zoetis?
Shares of ZTS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Zoetis' stock price today?
One share of ZTS stock can currently be purchased for approximately $90.73.
How big of a company is Zoetis?
Zoetis has a market capitalization of $42.32 billion and generates $5.31 billion in revenue each year. The company earns $864 million in net income (profit) each year or $2.40 on an earnings per share basis. Zoetis employs 9,200 workers across the globe.
What is Zoetis' official website?
How can I contact Zoetis?
Zoetis' mailing address is 10 Sylvan Way, Parsippany NJ, 07054. The company can be reached via phone at 973-822-7000 or via email at [email protected]
MarketBeat Community Rating for Zoetis (NYSE ZTS)
MarketBeat's community ratings are surveys of what our community members think about Zoetis and other stocks. Vote "Outperform" if you believe ZTS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZTS will underperform the S&P 500 over the long term. You may vote once every thirty days.
